New role of ID3 in melanoma adaptive drug-resistance

Adaptive resistance to targeted therapy such as BRAF inhibitors represents in melanoma a major drawback to this otherwise powerful treatment. Some of the underlying molecular mechanisms have recently been described: hyperactivation of the BRAF-MAPK pathway, of the AKT pathway, of the TGFβ/EGFR/PDGFR...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Sachindra, Larribère, Lionel, Novak, Daniel, Wu, Huizi, Hüser, Laura, Granados, Karol, Orouji, Elias, Utikal, Jochen
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2017
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5746373/
https://ncbi.nlm.nih.gov/pubmed/29299138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22698
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items